№ files_lp_4_process_1_33014
File format: docx
Character count: 1311
File size: 205 KB
Patient letter detailing a prescription medication update and instructions for switching from Fostair® inhaler to Proxor® inhaler, including contact information for support and guidance on usage.
Year:
2026
Region / City:
Nottingham and Nottinghamshire, UK
Subject:
Prescription medication update
Document Type:
Patient letter
Organization / Institution:
NHS Nottingham and Nottinghamshire Integrated Care Board
Author:
Dr X
Target Audience:
Patients prescribed Fostair®
Medication:
Fostair® (beclometasone/formoterol) and Proxor® (beclometasone/formoterol)
Purpose:
Inform patients of inhaler switch and guidance on use
Date Issued:
2026-03-11
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Note:
Region / City
Topic:
Asthma Treatment
Document Type:
Quick Reference Guide
Organization / Institution:
LSCMMG
Target Audience:
Medical professionals, Patients over 12 years of age
Title of research:
Automating patient inhaler technique when using pressurised Metered Dose Inhalers: testing the functionality and impact of the aflo™ digital respiratory management platform in a randomised controlled trial in a primary care setting
Type of document:
Participant information sheet
Study design:
Randomised controlled trial
Setting:
Primary care
Target population:
Children aged 5 years or over with a diagnosis of asthma
Inclusion criteria:
Diagnosis of asthma; confirmed suitable by GP; access to smartphone and WIFI/4G; currently prescribed a spacer; adherence or symptom control issues
Intervention:
aflo™ digital respiratory management platform and inhaler device
Control:
Standard care
Study duration:
24 weeks
Appointments:
Three visits (baseline, 12 weeks, 24 weeks)
Procedures:
Questionnaires; inhaler technique demonstration; blood pressure measurement; lung function test; spirometry data access; blood sample collection
Sample collection:
Up to 8 ml blood at first appointment
Funding body:
Respiratory Analytics Ltd
Ethics approval:
West Midlands - Edgbaston Research Ethics Committee; MHRA
Compensation:
Travel reimbursement and £20 voucher
Data handling:
Anonymised data analysis; GP access to results
Note:
Year
Topic:
Asthma, Education, Health Management
Document Type:
Assessment Tool
Target Audience:
School personnel, parents, healthcare providers
Year:
2023
Region / City:
Cambridge, England
Subject:
Respiratory medicine, dry powder inhalers, design optimization
Document Type:
Research article
Organization / Institution:
Cambridge Healthcare Innovations, BnL Pharma Solutions, Owlstone Medical
Author:
Heather Jameson, David Harris, Jacob Harker, Karina Joyce, Helen Samuel, Max Allsworth
Target Audience:
Researchers, engineers, professionals in respiratory medicine and inhaler technology
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A
Note:
Year
Subject:
Asthma, COPD, Health
Document Type:
Instructional Guide
Organization / Institution:
Somerset CCG
Target Audience:
Patients with asthma or COPD
Context:
Instructional guide for patients on how to properly use the Accuhaler inhaler, including troubleshooting and common mistakes.
Document type:
Patient information leaflet
Medical device:
Spiromax inhaler
Related conditions:
Asthma; Chronic obstructive pulmonary disease (COPD)
Examples of products:
DuoResp Spiromax; Aerivio Spiromax
Purpose:
Guidance on correct inhaler technique and maintenance
Reassessment interval:
3 months; 6 months; 12 months
Intended audience:
Patients prescribed Spiromax inhalers
Issuing context:
Healthcare professional instruction
Associated resource:
Online video demonstrations
Year:
2026
Region / City:
Nottingham, UK
Subject:
Dry powder inhaler testing, aerodynamic particle size distribution
Document Type:
Research article
Institution:
Copley Scientific Ltd
Authors:
Ben Bradley, Mark Copley
Target Audience:
Scientists and laboratory technicians in pharmaceutical R&D and quality control
Tested Devices:
Symbicort® Turbohaler®
Experimental Methods:
Andersen Cascade Impactor (ACI), Next Generation Impactor (NGI), Fast Screening Andersen (FSA), Fast Screening Impactor (FSI)
Key Variables:
Flow rate rise-time, flow resistance, apparatus volume
Study Purpose:
To match flow rate rise-time profiles of abbreviated and full resolution impactors using a variable volume and flow resistance compensator
Year:
Not specified
Region / city:
Not specified
Subject:
Inhaler usage, asthma, COPD
Document type:
Instructional guide
Organization:
Not specified
Author:
Not specified
Target audience:
Patients with asthma and COPD
Effective period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2026
Region / City:
International
Topic:
Respiratory health, asthma, COPD
Document type:
Patient information leaflet
Organization / Institution:
Pharmaceutical company / Healthcare provider
Author:
Not specified
Target audience:
Patients prescribed Ellipta inhalers
Medication examples:
Relvar Ellipta, Anoro Ellipta, Incruse Ellipta
Common issues addressed:
Incorrect inhaler technique, dose management
Reference materials:
Video demonstration link provided
Review period:
At least annually
Year:
2020
Region:
Australia
Subject:
Asthma treatment; inhaled corticosteroids; combination therapy
Document type:
Regulatory submission summary
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Company:
Chiesi Australia Pty Ltd
Drug:
Fostair® (Beclometasone dipropionate 100 µg + Formoterol fumarate 6 µg)
Population:
Adults with asthma requiring ICS/LABA therapy
Comparator:
Budesonide/Formoterol (BUD/FOR 200/6) and other ICS/LABA formulations
Approval status:
TGA approved 12 February 2020
Therapy type:
Maintenance and reliever therapy (MART)
Clinical claim:
Non-inferior efficacy and safety compared to BUD/FOR 200/6 MART
Endpoints:
Time to first severe exacerbation, exacerbation rate, FEV1, ACQ score, reliever use
Submission type:
Category 2, Authority Required (Streamlined) listing
Context:
Regulatory source detailing clinical efficacy, safety, and PBS listing considerations for BEC/FOR 100/6 as a combined maintenance and reliever asthma therapy.
Year:
2026
Region / City:
Not specified
Subject:
Respiratory health, asthma, COPD
Document type:
Patient instruction guide
Organization:
SWYAPC
Author:
Healthcare professionals
Target audience:
Patients using Genuair inhalers
Review period:
3, 6, and 12 months
Related resources:
https://www.swyapc.org/inhaler-videos/
Year:
2023
Region / City:
Global
Topic:
Inhaler usage instructions
Document Type:
Instructional guide
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Patients with asthma and chronic obstructive pulmonary disease (COPD)
Period of Use:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2026
Region / City:
International
Subject:
Respiratory health, inhaler use
Document type:
Patient instruction leaflet
Organization / Institution:
Healthcare providers / Spiromax manufacturer
Target audience:
Patients with asthma or COPD
Medication mentioned:
Spiromax inhaler
Common issues addressed:
Incorrect inhaler technique, dosage errors
Recommended actions:
Proper usage steps, cleaning, monitoring dose counter
Supplementary material:
Video demonstration link
Frequency of review:
At least annually
Year:
N/A
Region / City:
N/A
Topic:
Asthma, COPD, Inhaler Use
Document Type:
User Guide
Organization:
N/A
Author:
N/A
Target Audience:
Patients prescribed inhalers for asthma or COPD
Validity Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Note:
Context
Tematika:
Asthma ir lėtinė obstrukcinė plaučių liga (COPD) gydymas
Dokumento tipas:
Paciento informacinė instrukcija
Medicinos sritis:
Kvėpavimo sistemos ligos
Naudojamas prietaisas:
Turbohaler inhaliatorius
Pavyzdiniai vaistai:
Bricanyl Turbohaler; Oxis Turbohaler; Pulmicort Turbohaler; Symbicort Turbohaler
Tikslinė auditorija:
Pacientai, kuriems paskirti inhaliatoriai
Pagrindinė tema:
Taisyklinga inhaliatoriaus naudojimo technika
Kontrolinis sąrašas:
Turbohaler naudojimo žingsniai
Dažnos klaidos:
Netinkama inhaliatoriaus padėtis; neteisingas dozės paruošimas; per silpnas įkvėpimas; drėgmės patekimas į prietaisą
Papildomos rekomendacijos:
Burnos skalavimas po kortikosteroidų vartojimo; dangtelio uždėjimas po naudojimo
Stebėjimo laikotarpis:
3 mėnesiai; 6 mėnesiai; 12 mėnesių
Papildomi ištekliai:
Vaizdo instrukcijos apie inhaliatorių naudojimą
Šaltinio tipas:
Sveikatos priežiūros informacinė medžiaga